Fallara G, Robesti D, Nocera L, Raggi D, Marandino L, Belladelli F, Montorsi F, Malavaud B, Ploussard G, Necchi A, Martini A. Chemotherapy and Advanced Androgen Blockage, Alone or Combined, for Metastatic Hormone-Sensitive Prostate Cancer A systematic review and Meta-Analysis. Cancer Treat Rev 2022;110:102441. [DOI: 10.1016/j.ctrv.2022.102441] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Revised: 07/18/2022] [Accepted: 07/22/2022] [Indexed: 11/24/2022]

Martini A, Pfail J, Montorsi F, Galsky MD, Oh WK. Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial. Prostate Cancer Prostatic Dis 2020;23:638-645. [DOI: 10.1038/s41391-020-0231-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Revised: 03/20/2020] [Accepted: 03/31/2020] [Indexed: 01/22/2023]

Rescigno P, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin AG, Schmid S, Caffo O, Zivi A, Pezaro CJ, Morley C, Olmos D, Romero-Laorden N, Castro E, Saez MI, Mehra N, Smeenk S, Sideris S, Gil T, Banks P, Sandhu SK, Sternberg CN, De Giorgi U, De Bono JS. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. Eur Urol Oncol 2020;3:176-182. [DOI: 10.1016/j.euo.2019.06.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Accepted: 06/12/2019] [Indexed: 10/26/2022]